Founded with a mission to harness the power of the body’s endocannabinoid system, Isosceles Pharmaceuticals is a preclinical biotech company focused on developing innovative solutions for acute pain management. The company aims to reduce pain and inflammation through its perioperative acute pain product candidates, utilizing active ingredients with an approved drug master file and a proven safety profile. Their market focus is on providing safer, more effective pain relief options to improve patient outcomes.

Isosceles Pharmaceuticals has garnered attention for its pioneering approach in the biotech industry. Notable affiliated individuals and investors include experts in pharmacology and biotechnology, although specific names are not publicly disclosed. The company's key achievements include advancing its product candidates through preclinical stages, demonstrating significant potential in pain management. Overall, Isosceles Pharmaceuticals is making a substantial impact by developing safer alternatives for acute pain relief, aiming to enhance the quality of life for patients worldwide.